Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Inulin and Arabinoxylan on Satiety, Energy/Food Intake and Changes in the Human Gut Microbiota (MIXSAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02846454
Recruitment Status : Unknown
Verified May 2018 by Dr Daniel Commane, University of Reading.
Recruitment status was:  Recruiting
First Posted : July 27, 2016
Last Update Posted : May 11, 2018
Sponsor:
Information provided by (Responsible Party):
Dr Daniel Commane, University of Reading

Brief Summary:
This proposed randomized, double blinded 12 week crossover human feeding study aims to investigate the effects of consuming a composite drink of inulin and arabinoxylan on satiety by measuring appetite biomarkers such as subjective satiety, energy/food intake and changes in the human gut microbiota in healthy weight males (22 to 24.9kg/m2)

Condition or disease Intervention/treatment Phase
Overweight and Obesity Other: inulin Other: arabinoxylan Not Applicable

Detailed Description:

Research that focuses on the mechanisms involved in appetite regulation is topical given the emergence of the worldwide obesity epidemic. Understanding the physiological processes associated with the onset of obesity is essential for the development of effective anti-obesity strategies. There is evidence that people who consume a diet high in non-starch polysaccharides (NSPs) have a lower body mass index (BMI) than those that do not.

A 2009 review of fibre and satiety by Bridget Benelam, 2009 focused on different types of fibre and the significant impact they may have on satiety and/or energy intake, through fermentation of fibre such as non starch polysaccharides in the colon by gut bacterial groups such as Bifidobacterium. non starch polysaccharides and other fibre sources are poorly digested by human enzymes in the small intestine but are degraded by large groups of bacteria in the large bowel. One of the beneficial outcomes of this fermentation of fibre that gut bacteria produce of metabolites called short chain fatty acids (SCFA) thought to affect appetite regulation by stimulating production of satiety hormones that can help you feel full. Acetate and propionate are two of these metabolites highlighted as potential mediator of satiety.

Some fibres are called prebiotics as they act as selective sources for beneficial gut bacteria. However Western populations do not consume natural prebiotics in high quantities in their diet and the overall intake of fibre is also low. Therefore, in this study, the investigators aim to utilise a mixture of prebiotics in order to increase the growth and/or activity of commensal gut bacteria and SCFA production in human volunteers and to assess the effects of consumption on satiety.

Testing the impact of a composite mix of inulin and arabinoxylan in a human study will help determine the effect it has on appetite regulation, ad libitum food intake, SCFA production, anthropometric measurements, cognitive state (e.g. mood) and composition of the gut microbiota.

The study design is a 12 week randomized, human feeding study, with a crossover design testing a composite mix of inulin and arabinoxylan against an equivalent energy matched (kcal) maltodextrin control drink in 33 healthy weight (22 to 24.9kg/m2) males aged between 21-55. Volunteers will be enrolled to treatment or placebo for four weeks, with a four week wash out before the crossover. the primary endpoint, satiety following a test meal challenge will be measured on four occasions throughout the study. Anthropometry measures, dietary intake, body weight and blood pressure will be monitored throughout the study. Faecal and urine will be collected at baseline and at the end of each treatment period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Investigating the Effects of a Composite Drink of Inulin and Arabinoxylan on Satiety, Energy/Food Intake and Changes in the Human Gut Microbiota
Study Start Date : August 2016
Estimated Primary Completion Date : July 1, 2018
Estimated Study Completion Date : July 1, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Inulin

Arm Intervention/treatment
Experimental: inulin
Investigating the satiating effects of consuming 4g/d inulin (Fruitafit IQ by CHIMAB)
Other: inulin
Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
Other Name: Inulin (Fruitafit IQ)

No Intervention: non inulin and arabinoxylan
investigating the satiating effects of a control drink (2.6g/d maltodextrin)
Experimental: arabinoxylan
Investigating the satiating effects of consuming 4g/d arabinoxylan (Medium Chain Naxus, BioActor b.v)
Other: arabinoxylan
Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
Other Name: arabinoxylan (Naxus)




Primary Outcome Measures :
  1. Effects of consuming a composite drink of inulin and arabinoxylan on subjective satiety scores [ Time Frame: 6hrs ]
    The volunteers will randomized to receive either control or treatment drink and asked to consume this twice daily for 28 days, followed by a 28 day washout, the alternate drink will then be consumed for a further 28 days. Visual analogue scale will be used to measure subjective satiety scores during 4 half day study days lasting 6hrs at the beginning and end of each treatment period at a designated nutrition unit (Hugh Sinclair Nutrition unit, Reading University).


Secondary Outcome Measures :
  1. Effects of consuming a composite drink of inulin and arabinoxylan on energy intake [ Time Frame: 6hr ]
    Energy intake will be measured during each of the 4 study days. A test meal of cheese and tomato pizza will be given ad libitum as a lunch meal and the energy intake (KJ) will be measured by weighing the food before and after consumption.

  2. Effects of consuming a composite drink of inulin and arabinoxylan on anthropometric measurements [ Time Frame: 12 weeks ]
    In order to see if consumption of inulin and arabinoxylan have impacted anthropometric measurements, these will also be taken at the beginning of each of the 4 study days including height (m), weight (kg), waist and hip circumference (cm).

  3. Effects of consuming a composite drink of inulin and arabinoxylan on mediating changes in gut microbiota [ Time Frame: 28 days ]
    To assess the changes in faecal bacteria populations using fluorescent in situ hybridisation (FISH) will be used in which molecular probes target 16S ribosomal ribonucleic acid (rRNA),labelled with the fluorescent Cy3 dye (Sigma Aldrich Ltd., Poole, Dorset, UK) and as previously described by Martín-Peláez S et al 2008

  4. Effects of consuming a composite drink of inulin and arabinoxylan on the production of short chain fatty acid production. [ Time Frame: 28 days ]
    Analysis of SCFA production will be measured in millimolar (mM) by High Performance Liquid Chromotography (HPLC) and analysis using quantitative analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males
  • 21-55 years old
  • Body Mass Index (BMI) 19.5-24.5kg/m2
  • Overall healthy
  • Weight Stable (<3 kg change in the past 4 months, before the trial).

Exclusion Criteria:

  • Smokers
  • drink more than 28 units of alcohol per week (i.e. not more than 14 pints of beer or 28 small glasses of wine)
  • Restricted diet such as weight loss, vegetarian/vegan or taking dietary supplements such as prebiotics (such as oligosaccharides ie Fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS) or probiotics (ie Actimel)), not eating breakfast and >25g/d dietary fibre consumption as well as those with food allergies
  • Gastrointestinal procedure or surgery in the past three months.
  • Gastrointestinal disorders: celiac disease, Intestinal Bowel Disease (IBD), irritable bowel syndrome (IBS), chronic constipation, diverticulitis or a history of chronic constipation, diarrhoea, or other chronic gastrointestinal complaints
  • Disorders of swallowing, severe dysphagia to food or pills.
  • Appetite modulator drugs: orlistat, sibutramine, rimonabant.
  • Mood disorder medications: antidepressants, lithium.
  • Chronic metabolic conditions: diabetes, hepatic disease, gout, kidney, thyroid or coagulation disease.
  • Psychiatric disorder: severe depression, bulimia, anorexia, schizophrenia, bipolar disorder.
  • Pregnancy
  • Others: oral antidiabetics, insulin, digoxin, thyroid hormones, antibiotics, steroids or immunosuppressants, recreational substances.
  • Use of implanted or portable electro-mechanical device such as cardiac peacemaker or infusion pump.
  • Blood donor in the past 3 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02846454


Contacts
Layout table for location contacts
Contact: Daniel M Commane, PhD 0118 378 7108 d.m.commane@reading.ac.uk
Contact: sineaid M collins, BSC s.collins@pgr.reading.ac.uk

Locations
Layout table for location information
United Kingdom
Mr Daniel commane Recruiting
Reading, Berkshire, United Kingdom, RG6 6AH
Contact: Sineaid M collins, BSc       s.collins@pgr.reading.ac.uk   
Contact: Michelle Weech, PhD    0118 378 7771    m.weech@reading.ac.uk   
Sponsors and Collaborators
University of Reading
Investigators
Layout table for investigator information
Study Chair: Mike Proven, PhD Ethics committee Co-ordinator
Publications:
Layout table for additonal information
Responsible Party: Dr Daniel Commane, Principal Investigator, University of Reading
ClinicalTrials.gov Identifier: NCT02846454    
Other Study ID Numbers: UReading
First Posted: July 27, 2016    Key Record Dates
Last Update Posted: May 11, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Overweight
Body Weight